Categories: NewsVaccine

Benchling Announces Collaboration with Merck on Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment

SAN FRANCISCO, June 11, 2025 /PRNewswire/ — Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck’s pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting.

“Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis,” said Sajith Wickramasekara, co-founder and CEO of Benchling. “By focusing on the modern demands of bioanalytical labs, we’re delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle.”

 “Sophisticated data management capabilities are integral to advancing vaccine research and development,” said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. “We’re thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process.”

About Benchling

Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. With software purpose-built for biology, Benchling is on a mission to unlock the power of biotechnology. To learn more, visit Benchling.com.

View original content:https://www.prnewswire.com/news-releases/benchling-announces-collaboration-with-merck-on-vaccine-bioanalysis-302478378.html

SOURCE Benchling

Staff

Recent Posts

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

PALO ALTO, Calif., Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial…

47 minutes ago

Nested Knowledge and Pharmacy Podcast Network Announce Strategic Collaboration to Advance Evidence-Based Podcasting in Healthcare

New partnership combines AI-powered evidence synthesis with trusted pharmacist-led audio content to elevate clinical education…

47 minutes ago

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

ST. PAUL, Minn., Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it…

7 hours ago

2026 Brings Sharp 21% Spike in Health Insurance Premiums – Squeezing Household Budgets

ValuePenguin finds in 45 states, 2026 Health Insurance Premiums are Increasing by More Than 10%…

7 hours ago

Bioassay Method Transfer Strategies to Reduce Variability, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how to identify sources of variability in bioassay method transfers…

7 hours ago